Skip to main content
. 2016 Dec 3;8(5):7559–7571. doi: 10.18632/oncotarget.13791

Figure 4. Etanercept and adalimumab downregulate NFκB and STAT3 expression in human Th17-polarized cells.

Figure 4

(A) Th17-polarized cells were induced from purified CD4+ T cells from healthy subjects. Etanercept at 1 μg/ml and (B) adalimumab at 1 and 10 μg/ml decreased pp65 levels in human Th17-polarized cells. (C) Etanercept at 0.1 and 1 μg/ml and (D) adalimumab at 10 μg/ml decreased pSTAT3 levels in human Th17-polarized cells. For western blot analysis, the standard deviations of the optical density data were calculated for three independent experiments, and one experiment representative of the set of three is shown. *P < 0.05 for the comparison of Th17-polarized conditions with or without etanercept or adalimumab pretreatment.